Trending: Real estate giant JLL teams up with Google on new digital assistant app for office workers, challenging Alexa and Cortana


Shares of Seattle Genetics fell nearly 15 percent on Tuesday after the U.S. Food and Drug Administration placed clinical holds on its SGN-CD33A drug for acute myeloid leukemia (AML).

The company announced that “hepatotoxicity” occurred in patients treated with SGN-CD33A. Six patients have been identified with hepatotoxicity — including several cases of veno-occlusive disease, the company wrote. Four patients have died.

“Seattle Genetics is working diligently with the FDA to determine whether there is any association between hepatotoxicity and treatment with SGN-CD33A, to promptly identify appropriate protocol amendments for patient safety and to enable continuation of these trials,” the company wrote in a press release.

The company said that the “phase 1/2 trial of SGN-CD33A monotherapy in pre- and post-allogeneic transplant AML patients has been placed on full clinical hold.” Two of the company’s phase 1 trials have been placed on partial clinical hold, meaning no new enrollment and existing patients can continue with the trial with “re-consent.”

Shares of Seattle Genetics were trading at $52.88 on Tuesday morning, down more than 14 percent. The company is valued at $7.64 billion.

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline


Job Listings on GeekWork

Find more jobs on GeekWork. Employers, post a job here.